Ranked #2,468 of 8,699 institutional investors
Opaleye Management Inc.
Boston, MA
$935M
US stock portfolio at live prices · today −$5.3M (−0.56%)
Market closed. Prices as of Nov 20, 9:11 AM ET
- Value at quarter end (Q3 2026)
- $883M
- Change from Q2 2026
- −$221.2M (−20.03%)
- Positions
- 49 · 9 new, 8 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$186M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesETON 16.0%LQDA 12.8%IRON 8.91%HROW 7.23%TGTX 3.86%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| ETON Eton Pharmaceuticals, Inc. | 2,440,000 | $150M | 16.0% | Reduced −15% |
| LQDA Liquidia Corporation | 2,110,000 | $119M | 12.8% | Reduced −14% |
| IRON Disc Medicine, Inc. | 1,095,000 | $83.3M | 8.91% | Added +28% |
| HROW Harrow, Inc. | 2,105,000 | $67.6M | 7.23% | Reduced −12% |
| TGTX TG Therapeutics, Inc. | 557,000 | $36.1M | 3.86% | Added +4% |
| ACOG Alpha Cognition Inc. | 3,303,904 | $29.2M | 3.13% | Added +14% |
| REPL Replimune Group, Inc. | 1,384,993 | $26.6M | 2.85% | Unchanged |
| IMMX Immix Biopharma, Inc. | 2,825,000 | $19.9M | 2.13% | Added +20% |
| VSTM Verastem, Inc. | 2,753,333 | $18.9M | 2.02% | Added +53% |
| STOK Stoke Therapeutics, Inc. | 692,181 | $18.6M | 1.99% | Reduced −1% |
| RZLT Rezolute, Inc. | 4,087,045 | $17.2M | 1.84% | Reduced −35% |
| RVMD Revolution Medicines, Inc. | 100,000 | $15.9M | 1.70% | Unchanged |
| RYTM Rhythm Pharmaceuticals, Inc. | 122,500 | $14.3M | 1.53% | Unchanged |
| PTGX Protagonist Therapeutics, Inc. | 100,000 | $12.4M | 1.33% | Unchanged |
| SMMT Summit Therapeutics Inc. | 1,051,901 | $11.1M | 1.19% | New |
| QTTB Q32 Bio Inc. | 1,120,000 | $9.5M | 1.02% | Added +20% |
| GLUE Monte Rosa Therapeutics, Inc. | 1,035,000 | $9.2M | 0.99% | Added +39% |
| HRMY Harmony Biosciences Holdings, Inc. | 230,000 | $7.6M | 0.81% | New |
| EWTX Edgewise Therapeutics, Inc. | 175,000 | $7.2M | 0.77% | Reduced −65% |
| EDIT Editas Medicine, Inc. | 3,486,452 | $6.0M | 0.64% | Reduced −10% |
| GRCE Grace Therapeutics, Inc. | 2,798,167 | $4.8M | 0.52% | New |
| GOSS Gossamer Bio, Inc. | 426,989 | $4.8M | 0.51% | New |
| ALMS Alumis Inc. | 1,001,900 | $4.3M | 0.46% | Added +82% |
| TRVI Trevi Therapeutics, Inc. | 310,000 | $4.3M | 0.45% | Unchanged |
| LYEL Lyell Immunopharma, Inc. | 291,353 | $4.0M | 0.42% | Reduced −15% |
| FDMT 4D Molecular Therapeutics, Inc. | 334,437 | $3.6M | 0.38% | Unchanged |
| INBX Inhibrx Biosciences, Inc. | 45,500 | $3.4M | 0.36% | Added +124% |
| RLMD Relmada Therapeutics, Inc. | 1,000,000 | $3.1M | 0.33% | Added +7% |
| IRD Opus Genetics, Inc. | 750,000 | $3.1M | 0.33% | Reduced −33% |
| ANNX Annexon, Inc. | 875,000 | $3.0M | 0.32% | Reduced −49% |
| OCUL Ocular Therapeutix, Inc. | 506,436 | $3.0M | 0.32% | Reduced −16% |
| SNDX Syndax Pharmaceuticals, Inc. | 315,171 | $2.9M | 0.31% | New |
| CDXS Codexis, Inc. | 2,590,000 | $2.7M | 0.29% | Reduced −62% |
| VYGR Voyager Therapeutics, Inc. | 1,630,000 | $2.6M | 0.28% | Added +38% |
| BLSM BlossomHill Therapeutics, Inc. | 175,000 | $2.5M | 0.27% | New |
| CABA Cabaletta Bio, Inc. | 2,321,602 | $2.3M | 0.25% | Reduced −40% |
| JBIO Jade Biosciences, Inc. | 140,463 | $2.1M | 0.23% | Reduced −3% |
| RCKT Rocket Pharmaceuticals, Inc. | 1,000,000 | $2.1M | 0.23% | Unchanged |
| ZNTL Zentalis Pharmaceuticals, Inc. | 1,412,656 | $1.9M | 0.21% | Unchanged |
| FBIO Fortress Biotech, Inc. | 720,000 | $1.3M | 0.14% | Reduced −19% |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 630,000 | $1.2M | 0.13% | Reduced −10% |
| MBX MBX Biosciences, Inc. | 20,000 | $1.1M | 0.11% | Reduced −92% |
| ENTA Enanta Pharmaceuticals, Inc. | 125,000 | $998K | 0.11% | Unchanged |
| OBX Obsidian Therapeutics, Inc. | 75,755 | $920K | <0.1% | New |
| KRRO Korro Bio, Inc. | 69,348 | $845K | <0.1% | New |
| BDSX Biodesix, Inc. | 87,000 | $722K | <0.1% | Reduced −52% |
| SNWV SANUWAVE Health, Inc. | 306,140 | $487K | <0.1% | Unchanged |
| DERM Journey Medical Corporation | 125,000 | $444K | <0.1% | Reduced −64% |
| SION Sionna Therapeutics, Inc. | 70,000 | $208K | <0.1% | New |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| TRAX First Tracks Biotherapeutics, Inc. | 65,000 | $2.9M |
| NTLA Intellia Therapeutics, Inc. | 250,000 | $2.4M |
| COAG Hemab Therapeutics Holdings, Inc. | 47,652 | $1.9M |
| CGON CG Oncology, Inc. | 17,789 | $1.5M |
| KTTA Pasithea Therapeutics Corp. | 2,050,000 | $986K |
| PHAT Phathom Pharmaceuticals, Inc. | 185,589 | $943K |
| AVIR Atea Pharmaceuticals, Inc. | 235,000 | $924K |
| PTN Palatin Technologies, Inc. | 20,500 | $101K |